The global Epigenetics Market, valued at USD 2.03 billion in 2024, increased to USD 2.24 billion in 2025 and is projected to grow at a robust CAGR of 11.3% from 2025 to 2030, reaching an estimated USD 4.29 billion by the end of the forecast period.

Market growth is primarily driven by technological advancements, the increasing adoption of epigenetic tools in clinical diagnostics, and the rising prevalence of chronic diseases. Additionally, expanding biopharmaceutical research and development (R&D) activities and the growing need for precision medicine are significantly contributing to market expansion. The notable rise in oncology research has also spurred demand for advanced epigenetic analysis tools and services. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) into epigenetic workflows is enhancing data interpretation and research efficiency, thereby accelerating market growth.
Download PDF Brochure

Market Segmentation by Offering

The global market is segmented by offering into kits and reagents, enzymes, instruments and accessories, software, and services.

Within the kits and reagents category, sub-segments include:

• Antibodies
• ChIP-sequencing kits and reagents
• Bisulfite conversion kits and reagents
• Whole-genome amplification kits and reagents
• 5-hmC and 5-mC analysis kits and reagents
• Histones
• Other related kits and reagents

In 2024, the antibodies segment is expected to command the largest market share. This dominance is attributed to the growing dependence on antibodies for detecting, identifying, and modifying proteins, as well as their essential role in monitoring cellular regulation and gene expression. Ongoing technological improvements are anticipated to further strengthen the growth trajectory of this segment throughout the forecast period.

Market Segmentation by Methodology

Based on methodology, the epigenetics market is categorized into:

• DNA Methylation
• Histone Modifications
• Other Approaches, including non-coding RNA interactions and chromatin remodeling

The DNA methylation segment is projected to record a strong CAGR over the forecast period, primarily due to its proven reliability and effectiveness in oncology research applications, where it plays a crucial role in studying gene silencing and tumor progression.

Regional Insights

The Asia-Pacific (APAC) region is anticipated to witness the fastest growth in the epigenetics market through 2030. Key drivers include the expansion of local biotechnology companies, increased strategic alliances and collaborations, and continuous improvement in healthcare infrastructure across emerging economies. Moreover, growing expertise in Next-Generation Sequencing (NGS) technologies is further fueling regional market development.

North America remains a key market due to its strong research ecosystem, advanced healthcare infrastructure, and substantial investments from leading industry players. Europe also contributes significantly, driven by supportive regulatory frameworks, academic collaborations, and government funding for life sciences research.

Key Market Players

Prominent companies operating in the global epigenetics market include:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Illumina, Inc. (US)
• PacBio (US)
• Danaher Corporation (US)
• Active Motif, Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• Promega Corporation (US)
• Revvity (US)
• QIAGEN (Germany)

Company Highlights

Illumina Inc. (US)
In 2024, Illumina maintained its leading position in the genomics industry, supported by a strong client base that includes top pharmaceutical firms, biotechnology companies, academic research centers, and hospitals. With a dominant market share in Next-Generation Sequencing (NGS), Illumina is leveraging its technological strengths to expand into adjacent areas such as epigenetic sequencing. A major strategic milestone was reached in June 2025, when Illumina announced the acquisition of SomaLogic. This move strengthens Illumina’s foothold in the epigenetics domain and supports its broader multiomics strategy, integrating genomics, transcriptomics, proteomics, and epigenomics for deeper biological insights.

Thermo Fisher Scientific Inc. (US)
Thermo Fisher remains one of the most influential players in the global epigenetics market, supported by a diverse product portfolio and a global operational footprint. In July 2025, the company achieved U.S. FDA approval for its Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) tool for tumor profiling and companion diagnostics (CDx). Thermo Fisher continues to invest heavily in R&D, pursuing both organic and inorganic growth strategies. Its expansive distribution network and strong focus on customer support enable the delivery of advanced, reliable solutions, reinforcing its leadership position in the epigenetics market.